“The IPO (initial public offering) in October 2020 was a significant milestone for the company and has provided the funding to continue our momentum as we begin to transition into commercialisation in (financial year) 2022,” he said.
The company achieved several key milestones in its strategy during the period, including a successful, oversubscribed IPO. The company was listed on the NZX in October 2020, raising its targeted $20 million.
Rua deployed funds raised from the IPO across strategic priority areas that underpin achieving initial sales and revenue.
A company statement said it anticipated having product available for New Zealand patients as a prescription-only medicine in 2022, once it had obtained GMP certification, completed the New Medicines Application process and Ministry of Health's Quality Standard assessment, which are required for all new products.
Of the company's 30 staff as at balance date, 15 have whanau connections or whakapapa to Te Tairawhiti. These staff work at all levels of the organisation.